Introduction VAP-1 is an adhesion molecule which promotes lymphocyte recruitment to the liver. It is released in a soluble form (sVAP-1) from adipose tissue and the hepatic vascular bed. sVAP-1 has insulin-like effects, can initiate and propagate oxidative stress and is implicated in vascular complications of the metabolic syndrome. Our group has discovered that VAP-1 is expressed and secreted by hepatic stellate cells and we have reported that serum sVAP-1levelsareelevated in NAFLD and predict fibrosis. These observations suggest that VAP-1 may have a role in mediating interactions between lymphocytes and stromal cells to promote inflammation induced fibrosis in NAFLD.
Aim To investigate a possible pathogenic role for VAP-1 in NAFLD by determining the effects of the inhibition or absence of VAP-1 in murine models of steatohepatitis.
Method 1. A high fat diet (HFD) was administered for 18 weeks in wild type (WT) C57Bl/6 mice (n=5) and VAP-1 null mice (n=5). 2. A methionine choline deficient (MCD) diet was administered for 6 weeks in WT mice (n=6), WT mice receiving an anti-VAP-1 antibody (n=6) and VAP-1 null mice (n=6).
Results In the HFD model VAP-1 null mice developed less steatosis on quantitative analysis of Oil Red O staining (p<0.001) and had fewer inflammatory foci (p<0.05) than WT mice. They were also protected against the onset of fibrosis with less collagen deposition (p<0.001) and lower levels of hepatic gene expression of SMA (p<0.05) and collagen 1, α 1 (p<0.05). In the MCD model VAP-1 null and antibody treated mice were equally protected from liver injury; showing less steatosis (p<0.001), fewer inflammatory foci (p<0.001), less collagen staining (p<0.001) and lower hepatic SMA (p<0.001) and collagen type 1, α 1 (p<0.01) mRNA expression than WT mice. Both models of steatohepatitis resulted in increased hepatic gene expression of VAP-1 when compared with age sex matched mice on normal diet.
Conclusion ElevatedsVAP-1 levels in NAFLD and increased hepatic VAP-1 expression in murine steatohepatitis suggest a role for VAP-1 in the pathogenesis of NAFLD. Inhibition and/or absence of VAP-1 are protective in two murine models of steatohepatitis implicating an important role for VAP-1 in hepatic fibrogenesis and suggesting it may be a potential therapeutic target in NAFLD.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.